The Centers for Medicare & Medicaid Services yesterday released a proposed rule revising requirements for value-based purchasing agreements between states and manufacturers for drugs covered by Medicaid.

According to CMS, the rule would change how manufacturers calculate average manufacturer price for brand name drugs with an authorized generic, and determine whether to include the value of their patient assistance programs when calculating “best price.” It also would revise definitions and reporting requirements for the Medicaid Drug Rebate Program; coordination of benefit and third-party liability rules for certain care and payment in Medicaid and the Children’s Health Insurance Program; and set minimum standards for state Medicaid Drug Utilization Review in an effort to reduce opioid-related fraud, misuse and abuse, among other changes.

Related News Articles

Headline
The Oklahoma Health Care Authority this week withdrew its request for the Centers for Medicare & Medicaid Services to approve a Healthy Adult…
Headline
The Department of Health and Human Services yesterday announced it has expanded the providers eligible for its Public Health and Social Services Emergency Fund…
Headline
Missouri voters yesterday approved an expansion of the state’s Medicaid initiative, the second state to do so during the COVID-19 pandemic. The amendment,…
Headline
The Department of Health and Human Services Friday extended to Aug. 28 the deadline for eligible Medicaid, Children’s Health Insurance Program and dental…
Headline
The National Association of Medicaid Directors yesterday asked the Centers for Medicare & Medicaid Services to suspend finalizing the Medicaid Fiscal…
Headline
The Department of Health and Human Services July 27 at 3 p.m. ET will host a webinar on the Provider Relief Fund application process for eligible Medicaid,…